Prime Medicine Inc (NASDAQ: PRME) is -55.30% lower on its value in year-to-date trading and has touched a low of $3.28 and a high of $9.86 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PRME stock was last observed hovering at around $4.32 in the last trading session, with the day’s loss setting it -0.36%.
Currently trading at $3.96, the stock is -4.13% and 1.98% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.49 million and changing -8.33% at the moment leaves the stock -28.94% off its SMA200. PRME registered -40.59% loss for a year compared to 6-month loss of -41.42%. The firm has a 50-day simple moving average (SMA 50) of $3.8809 and a 200-day simple moving average (SMA200) of $5.58675.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 5.04% gain in the last 1 month and extending the period to 3 months gives it a -9.79%, and is -3.41% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.63% over the week and 8.11% over the month.
Prime Medicine Inc (PRME) has around 234 employees, a market worth around $475.32M and $0.80M in sales. Profit margin for the company is -27406.12%. Distance from 52-week low is 20.73% and -59.84% from its 52-week high. The company has generated returns on investments over the last 12 months (-96.90%).
The EPS is expected to grow by 25.52% this year
167.0 institutions hold shares in Prime Medicine Inc (PRME), with institutional investors hold 91.68% of the company’s shares. The shares outstanding are 97.38M, and float is at 39.57M with Short Float at 39.92%. Institutions hold 67.73% of the Float.
Prime Medicine Inc (PRME) Insider Activity
The most recent transaction is an insider purchase by NELSEN ROBERT, the company’s Director. SEC filings show that NELSEN ROBERT bought 3,200,000 shares of the company’s common stock on Feb 15 ’24 at a price of $6.25 per share for a total of $20.0 million. Following the purchase, the insider now owns 3.2 million shares.
Prime Medicine Inc disclosed in a document filed with the SEC on Feb 15 ’24 that ARCH Venture Partners XII, LLC (10% Owner) bought a total of 3,200,000 shares of the company’s common stock. The trade occurred on Feb 15 ’24 and was made at $6.25 per share for $20.0 million. Following the transaction, the insider now directly holds 3.2 million shares of the PRME stock.
Still, SEC filings show that on Feb 15 ’24, ARCH Venture Partners X, LLC (10% Owner) acquired 3,200,000 shares at an average price of $6.25 for $20.0 million. The insider now directly holds 3,200,000 shares of Prime Medicine Inc (PRME).
